- News Home
24 April 2014 11:45 am ,
Vol. 344 ,
Major climate data sets have underestimated the rate of global warming in the last 15 years owing largely to poor data...
The tsetse fly is best known as the vector for the trypanosome parasites that cause sleeping sickness and a disease in...
The National Institutes of Health is revising its "two strikes" rule, which allowed researchers only one chance to...
By stabilizing the components of retromers, molecular complexes that act like recycling bins in cells, a recently...
Fossil fuels power modern society by generating heat, but much of that heat is wasted. Semiconductor devices called...
Researchers are gaining insights into what made Supertyphoon Haiyan so powerful and devastating through post-storm...
Millions around the world got a first-hand look at what it was like to be in Tacloban while it was pummeled by...
- 24 April 2014 11:45 am , Vol. 344 , #6182
- About Us
Leukemia Drug and Magnet Material Net Japan Prizes
25 January 2012 10:21 am
TOKYO—A trio of American researchers will share one of this year's Japan Prizes for bringing their work on a leukemia drug from a basic discovery to a clinical success, while a Japanese material scientist is taking the other prize for a breakthrough with permanent magnets.
Janet Rowley of the University of Chicago, Brian Druker of the Oregon Health & Science University in Portland, and Nicholas Lydon of Blueprint Medicines in Cambridge, Massachusetts, jointly won the Healthcare and Medical Technology prize for developing a leukemia drug called imatinib, better known as Gleevec in the United States and Glivec elsewhere. In the 1970s, Rowley identified several chromosomal translocations—in which a part of one chromosome gets transferred to another—in patients suffering chronic myelogenous leukemia (CML). Lydon, then at Ciba-Geigy (now Novartis) in Basel, Switzerland, and Druker later collaborated to develop compounds that inhibit the activity of the abnormal enzyme resulting from the translocations, which causes runaway cell proliferation. They steered imatinib through clinical trials starting in 1998.
Now used as a once-a-day pill, the drug has made CML, once fatal within 3 to 5 years, "a manageable disease," Druker said at the prize announcement press conference today. He added that "hundreds of other drugs in development" are based on the same approach of blocking the activity of specific enzymes associated with a given type of cancer.
Masato Sagawa, of Kyoto-based Intermetallics Co., won the prize in the field of Environment, Energy, and Infrastructure for work on the neodymium-iron-boron alloy which constitutes the high-performance permanent magnets at the heart of energy-efficient motors used in everything from hard disk drives to construction equipment. Sagawa did his key research at Fujitsu Ltd. and Sumitomo Special Metals in the 1970s and 1980s. He continues to refine the material to extend the range of applications.
The three healthcare laureates will share equally one $650,000 award; Sagawa alone gets an equal sum. All four will receive their awards, including commemorative gold medals, at an April ceremony in Tokyo.